These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 33071772)

  • 21. The prion hypothesis of Parkinson's disease.
    Chu Y; Kordower JH
    Curr Neurol Neurosci Rep; 2015 May; 15(5):28. PubMed ID: 25868519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ɑ-Synuclein strains and the variable pathologies of synucleinopathies.
    Peelaerts W; Baekelandt V
    J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling α-Synuclein Propagation with Preformed Fibril Injections.
    Chung HK; Ho HA; Pérez-Acuña D; Lee SJ
    J Mov Disord; 2019 Sep; 12(3):139-151. PubMed ID: 31556259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy.
    Valera E; Monzio Compagnoni G; Masliah E
    Neuropathol Appl Neurobiol; 2016 Feb; 42(1):95-106. PubMed ID: 26924723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology.
    Manecka DL; Vanderperre B; Fon EA; Durcan TM
    Front Mol Neurosci; 2017; 10():311. PubMed ID: 29021741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. α-Synuclein in Parkinson's disease: causal or bystander?
    Riederer P; Berg D; Casadei N; Cheng F; Classen J; Dresel C; Jost W; Krüger R; Müller T; Reichmann H; Rieß O; Storch A; Strobel S; van Eimeren T; Völker HU; Winkler J; Winklhofer KF; Wüllner U; Zunke F; Monoranu CM
    J Neural Transm (Vienna); 2019 Jul; 126(7):815-840. PubMed ID: 31240402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations Between APOE Variants, Tau and α-Synuclein.
    Rodriguez-Vieitez E; Nielsen HM
    Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. α-Synuclein-112 Impairs Synaptic Vesicle Recycling Consistent With Its Enhanced Membrane Binding Properties.
    Soll LG; Eisen JN; Vargas KJ; Medeiros AT; Hammar KM; Morgan JR
    Front Cell Dev Biol; 2020; 8():405. PubMed ID: 32548120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study.
    Donadio V; Incensi A; El-Agnaf O; Rizzo G; Vaikath N; Del Sorbo F; Scaglione C; Capellari S; Elia A; Stanzani Maserati M; Pantieri R; Liguori R
    Sci Rep; 2018 Sep; 8(1):14246. PubMed ID: 30250046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium: Alpha-Synuclein Interactions in Alpha-Synucleinopathies.
    Rcom-H'cheo-Gauthier AN; Osborne SL; Meedeniya AC; Pountney DL
    Front Neurosci; 2016; 10():570. PubMed ID: 28066161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ɑ-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences.
    Peelaerts W; Bousset L; Baekelandt V; Melki R
    Cell Tissue Res; 2018 Jul; 373(1):195-212. PubMed ID: 29704213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. α-Synuclein Trafficking in Parkinson's Disease: Insights From Fly and Mouse Models.
    Cheng J; Lu Q; Song L; Ho MS
    ASN Neuro; 2018; 10():1759091418812587. PubMed ID: 30482039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies.
    Lemos M; Stefanova N
    Front Synaptic Neurosci; 2020; 12():586453. PubMed ID: 33041780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy.
    Venezia S; Refolo V; Polissidis A; Stefanis L; Wenning GK; Stefanova N
    Mol Neurodegener; 2017 Jul; 12(1):52. PubMed ID: 28676095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prion-like propagation of α-synuclein in neurodegenerative diseases.
    Tarutani A; Hasegawa M
    Prog Mol Biol Transl Sci; 2019; 168():323-348. PubMed ID: 31699325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical application of prion-like seeding in α-synucleinopathies: Early and non-invasive diagnosis and therapeutic development.
    Li J; Luo H; Zheng H; Duan S; Zhao T; Yuan Y; Liu Y; Zhang X; Wang Y; Yang J; Xu Y
    Front Mol Neurosci; 2022; 15():975619. PubMed ID: 36299857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.
    Peelaerts W; Bousset L; Van der Perren A; Moskalyuk A; Pulizzi R; Giugliano M; Van den Haute C; Melki R; Baekelandt V
    Nature; 2015 Jun; 522(7556):340-4. PubMed ID: 26061766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-synuclein and the prion hypothesis in Parkinson's disease.
    Melki R
    Rev Neurol (Paris); 2018 Nov; 174(9):644-652. PubMed ID: 30201422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
    Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
    Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.